- Home
- VRNA vs FHI Comparison
VRNA vs FHI Comparison
Compare VRNA & FHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNA
- FHI
- Stock Information
- Founded
- VRNA 2005
- FHI 1955
- Country
- VRNA United Kingdom
- FHI United States
- Employees
- VRNA N/A
- FHI N/A
- Industry
- VRNA Biotechnology: Pharmaceutical Preparations
- FHI Investment Managers
- Sector
- VRNA Health Care
- FHI Finance
- Exchange
- VRNA Nasdaq
- FHI Nasdaq
- Market Cap
- VRNA 3.2B
- FHI 3.5B
- IPO Year
- VRNA 2017
- FHI N/A
- Fundamental
- Price
- VRNA $43.06
- FHI $41.93
- Analyst Decision
- VRNA Strong Buy
- FHI Buy
- Analyst Count
- VRNA 6
- FHI 6
- Target Price
- VRNA $43.83
- FHI $43.33
- AVG Volume (30 Days)
- VRNA 1.0M
- FHI 515.4K
- Earning Date
- VRNA 11-04-2024
- FHI 01-23-2025
- Dividend Yield
- VRNA N/A
- FHI 2.97%
- EPS Growth
- VRNA N/A
- FHI 3.08
- EPS
- VRNA N/A
- FHI 3.16
- Revenue
- VRNA $5,624,000.00
- FHI $1,598,907,000.00
- Revenue This Year
- VRNA N/A
- FHI $2.08
- Revenue Next Year
- VRNA $644.06
- FHI $6.57
- P/E Ratio
- VRNA N/A
- FHI $13.26
- Revenue Growth
- VRNA 1127.95
- FHI 0.44
- 52 Week Low
- VRNA $11.39
- FHI $31.24
- 52 Week High
- VRNA $43.73
- FHI $43.92
- Technical
- Relative Strength Index (RSI)
- VRNA 61.99
- FHI 49.78
- Support Level
- VRNA $38.77
- FHI $41.64
- Resistance Level
- VRNA $43.73
- FHI $42.92
- Average True Range (ATR)
- VRNA 1.41
- FHI 0.68
- MACD
- VRNA 0.07
- FHI -0.22
- Stochastic Oscillator
- VRNA 60.80
- FHI 12.50
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
About FHI Federated Hermes Inc.
Federated Hermes provides asset-management services for institutional and individual investors. The firm had $800 billion in managed assets at the end of September 2024, composed of equity (10%), multi-asset (less than 1%), fixed-income (12%), alternative (3%), and money market (74%) funds. The firm's cash-management operations are expected to generate around 51% of Federated's revenue this year, compared with 29%, 12%, and 7%, respectively, for the equity, fixed-income, and alternatives/multi-asset operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (65% of AUM), institutional investors (26%), and international clients (9%).